Shelton Capital Management Vertex Pharmaceuticals Inc Transaction History
Shelton Capital Management
- $3.62 Billion
- Q2 2024
A detailed history of Shelton Capital Management transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Shelton Capital Management holds 47,708 shares of VRTX stock, worth $22.1 Million. This represents 0.62% of its overall portfolio holdings.
Number of Shares
47,708
Previous 47,478
0.48%
Holding current value
$22.1 Million
Previous $19.8 Million
12.67%
% of portfolio
0.62%
Previous 0.58%
Shares
26 transactions
Others Institutions Holding VRTX
# of Institutions
1,707Shares Held
226MCall Options Held
1.2MPut Options Held
1.59M-
Capital World Investors Los Angeles, CA26.7MShares$12.4 Billion2.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA23MShares$10.6 Billion0.21% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$9.87 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.7MShares$5.43 Billion0.24% of portfolio
-
Capital Research Global Investors Los Angeles, CA8.54MShares$3.95 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $119B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...